Given that IHC-assessed MET-protein expression does not seem to accurately predict MET-induced resistance to EGFR-TKIs or sensitivity to MET-inhibitors in EGFRM+ NSCLC, and since it is still debated whether MET:CEN ratio is the best predictor for these drugs [133,134,135], alternative indicators of downstream MET-activation by increased MET-gene expression might be necessary. The gene discussed is MET; the disease is non-small cell lung carcinoma.